Articles renew scrutiny of antianemia drug safety
FDA to review new data for dosage, risk
A set of articles to be published today in the New England Journal of Medicine is spurring new scrutiny of the use of antianemia drugs to boost red blood cell counts beyond Food and Drug Administration recommendations. (Full article: 776 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
